📊 RVPH Key Takeaways
Is Reviva Pharmaceuticals Holdings, Inc.. (RVPH) a Good Investment?
Reviva is a pre-commercial pharmaceutical company with critical financial distress: $14.4M in cash against $24.6M annual cash burn creates a 7-month runway to insolvency. Minimal revenue ($122.9K) against massive operating losses (-$20.2M) indicates unproven commercial viability and an unsustainable cost structure with high bankruptcy or dilution risk.
Why Buy Reviva Pharmaceuticals Holdings, Inc.. Stock? RVPH Key Strengths
- Revenue growing 81.5% YoY despite minimal base demonstrates emerging commercial traction
- Zero long-term debt eliminates refinancing risk and interest burden obligations
- Positive stockholders' equity of $8.6M provides asset base for potential restructuring or asset sales
RVPH Stock Risks: Reviva Pharmaceuticals Holdings, Inc.. Investment Risks
- Critical liquidity crisis: $24.6M annual cash burn against $14.4M cash creates 7-month runway
- Unsustainable cost structure with $20.2M operating losses against $122.9K revenue (16,440% negative operating margin)
- Pre-commercial stage with unproven product viability and uncertain path to profitability
- High probability of dilutive capital raise or bankruptcy without revenue inflection or major cost restructuring
- Burn rate accelerating relative to revenue growth suggests deteriorating financial condition
Key Metrics to Watch
- Monthly cash burn rate and cash runway to depletion
- Quarterly revenue growth trajectory and gross margin emergence
- Capital raise announcements and dilution percentage to shareholders
- Operating expense reduction initiatives and path to cash flow breakeven
Reviva Pharmaceuticals Holdings, Inc.. (RVPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.08x current ratio provides a solid financial cushion.
RVPH Profit Margin, ROE & Profitability Analysis
RVPH vs Healthcare Sector: How Reviva Pharmaceuticals Holdings, Inc.. Compares
How Reviva Pharmaceuticals Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Reviva Pharmaceuticals Holdings, Inc.. Stock Overvalued? RVPH Valuation Analysis 2026
Based on fundamental analysis, Reviva Pharmaceuticals Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Reviva Pharmaceuticals Holdings, Inc.. Balance Sheet: RVPH Debt, Cash & Liquidity
RVPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Reviva Pharmaceuticals Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.73 indicates the company is currently unprofitable.
RVPH Revenue Growth, EPS Growth & YoY Performance
Reviva Pharmaceuticals Holdings, Inc.. Dividends, Buybacks & Capital Allocation
RVPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Reviva Pharmaceuticals Holdings, Inc.. (CIK: 0001742927)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RVPH
What is the AI rating for RVPH?
Reviva Pharmaceuticals Holdings, Inc.. (RVPH) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RVPH's key strengths?
Claude: Revenue growing 81.5% YoY despite minimal base demonstrates emerging commercial traction. Zero long-term debt eliminates refinancing risk and interest burden obligations.
What are the risks of investing in RVPH?
Claude: Critical liquidity crisis: $24.6M annual cash burn against $14.4M cash creates 7-month runway. Unsustainable cost structure with $20.2M operating losses against $122.9K revenue (16,440% negative operating margin).
What is RVPH's revenue and growth?
Reviva Pharmaceuticals Holdings, Inc.. reported revenue of $122.9K.
Does RVPH pay dividends?
Reviva Pharmaceuticals Holdings, Inc.. does not currently pay dividends.
Where can I find RVPH SEC filings?
Official SEC filings for Reviva Pharmaceuticals Holdings, Inc.. (CIK: 0001742927) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RVPH's EPS?
Reviva Pharmaceuticals Holdings, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RVPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Reviva Pharmaceuticals Holdings, Inc.. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RVPH stock overvalued or undervalued?
Valuation metrics for RVPH: ROE of -229.7% (sector avg: 15%), net margin of -16,167.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RVPH stock in 2026?
Our dual AI analysis gives Reviva Pharmaceuticals Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RVPH's free cash flow?
Reviva Pharmaceuticals Holdings, Inc..'s operating cash flow is $-24.6M, with capital expenditures of N/A. FCF margin is -20,017.3%.
How does RVPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -16,167.8% (avg: 12%), ROE -229.7% (avg: 15%), current ratio 2.08 (avg: 2).